Navigation Links
Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMA's Fully Human Antibody Libraries for Their Discovery Platform
Date:7/30/2012

CRANBURY, N.J., July 30, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv) into a bi-specific antibody scaffold. Through the partnership, Oncobiologics will utilize XOMA's ADAPT™ fully human antibody technology platform as a key component of its drug discovery program. Oncobiologics has selected clinically validated targets that will be used in the development of its bi-specific antibody platform targeting three therapeutic areas: Oncology, Immuno-Oncology and Immunology.

Under the agreement, Oncobiologics will gain access to XOMA's highly diverse library of scFv antibodies and associated patent estate, and will utilize XOMA's know-how and proven software tools as it advances its own candidates for treating cancer and immune diseases. Financial terms were not disclosed.

Pankaj Mohan, Ph.D., Founder & CEO of Oncobiologics, commented, "We are very excited to partner with XOMA to advance our discovery pipeline. Their proven technology represents an important asset to support our strategy to deliver improved efficacy and safety in our drug candidates. Access to this technology is a key differentiator for the bi-specific mAb candidates in our pipeline and we believe this creates significant value for our programs."

Joseph Bertino, M.D., Chief Scientific Officer of the Cancer Institute of New Jersey and Head of Oncobiologics' Scientific Advisory Board, added, "Fully human single chain antibodies in a bi-specific format offer promising opportunities for a new class of biotherapeutics designed to enhance efficacy and safety. Bringing together these capabilities with Oncobiologics' platform creates an exciting pathway for enhancing oncology treatment."

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is a biopharmaceutical company developing a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. The company's proprietary TriDENT™ platform leverages fully human single-chain, bi-specific antibodies with HSA binding designed for overall significantly enhanced efficacy, safety, and pharmacokinetics with targeted delivery.  For more information, please visit www.oncobiologics.com or call 609-619-3990.

Contact:         

BUSINESS & TECHNICAL INQUIRIES
Stephen J. McAndrew, Ph.D.
Oncobiologics, Inc.
609-619-3990, ext. 216
stephenmcandrew@oncobiologics.com

MEDIA INQUIRIES
Rick Gregory
860-677-2377
rickgregory@oncobiologics.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.  


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group Announces Record Second Quarter Results
2. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
3. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
4. Leading India-USA based CRO Announces Data Management/EDC, Medical Writing Milestone
5. IDEXX Laboratories Announces Second Quarter Results
6. Amgen Announces 2012 Third Quarter Dividend
7. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
8. Critical Process Filtration Announces New Website and Expanded Literature Library
9. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
10. Neogen Corporation Announces Year-End Results Conference Call
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time ... US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. ... US2020. , US2020’s mission is to change the trajectory of STEM education in ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions ... scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):